The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point  by Messerli, Franz H.
E
w
e
t
a
d
r
s
m
t
t
b
b
t
p
d
o
g
F
U
i
N
F
h
B
2
Journal of the American College of Cardiology Vol. 53, No. 6, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PVIEWPOINT
The Sudden Demise of Dual
Renin-Angiotensin System Blockade
or the Soft Science of the Surrogate End Point
Franz H. Messerli, MD, FACC
New York, New York
Physicians have embraced the concept of dual renin-angiotensin system (RAS) blockade hoping that it would trans-
late into better blood pressure control as well as incremental nephroprotective and cardioprotective effects. With re-
gard to blood pressure, a small additional fall with dual RAS blockade was observed when compared with that seen
in monotherapy. Numerous studies have shown a reduction of albuminuria with dual RAS blockade. However, the
recent findings in the ONTARGET (Renal Outcomes With Telmisartan, Ramipril, or Both, in People at High Vascular
Risk) study of significantly more doubling of the creatinine and dialysis in the combination arm despite lesser albu-
minuria emphasized the fallacy of surrogate end points and argue against nephroprotective effects of dual RAS block-
ade. In heart failure, dual RAS blockade was associated with more hypotension, worsening of renal function, and hy-
perkalemia than was angiotensin-converting enzyme inhibitor therapy alone. In conclusion, recent outcome and
safety data have shattered the halo of dual RAS blockade for hypertension, nephroprotection, and heart failure.
Unless data emerge to the contrary, dual RAS blockade should no longer be used in clinical practice. (J Am
Coll Cardiol 2009;53:468–70) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.036B
M
s
A
fi
c
w
p
o
a
H
e
d
t
t
c
t
m
u
w
m
o
a
A
Nver since experimental data by Menard et al. (1) showed
hat was somewhat euphemistically called a “synergistic”
ffect of angiotensin-converting enzyme (ACE) inhibi-
ion and angiotensin receptor blockade (ARB), practicing
nd academic physicians have embraced the concept of
ual renin-angiotensin system (RAS) blockade. The
ationale behind dual RAS blockade derived from data
howing an escape phenomenon with ACE inhibitor
onotherapy resulting in angiotensin I accumulation and
hereby generating angiotensin II (2,3). It was hoped that
he addition of an ARB would provide a more complete
lockade of the RAS and that, indeed, a complete
lockade would translate into better blood pressure con-
rol as well as incremental nephroprotective and cardio-
rotective effects (3,4). So enticing was the concept of
ual RAS blockade that despite a lack of solid evidence
n safety and efficacy it found entrance into recent
uidelines (5).
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ost blood pressure studies showed a small additional drop in
ystolic and diastolic pressure when an ARB was added to an
CE inhibitor and vice versa, regardless of the dose level of the
rst drug. A thorough systematic review and meta-analysis (6)
ollected 14 blood pressure studies in hypertensive patients in
hich patients were evaluated by 24-h ambulatory blood
ressure monitoring. The authors found that the combination
f an ACE inhibitor and an ARB reduced blood pressure by an
verage of 4/3 mm Hg when compared with monotherapy.
owever, it was not clear whether this modest subadditive
ffect was attributable to an interaction between the 2 classes of
rugs because of their pharmacokinetic properties or whether
here was indeed a synergistic effect. The authors stated that in
heir opinion an appropriately designed study would show that
ombined RAS blockade confers little advantage over mono-
herapy with regard to blood pressure (6). Thus, for lowering of
illimeters of mercury there seems to be little if any reason to
se dual RAS blockade. The incremental fall in blood pressure
ith dual RAS blockade compared with that seen with
onotherapy is certainly a fraction only of what is commonly
bserved with the addition of either a thiazide or calcium
ntagonist.
lbuminuria
umerous studies have suggested benefits of dual RAS block-
de in patients with albuminuria or albuminuria when com-
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February 10, 2009:468–70 Sudden Demise of Dual RAS Blockadeared with either monotherapy with an ARB or an ACE
nhibitor (7). In a thorough meta-analysis of 49 studies
nvolving over 6,000 patients, Kunz et al. (8) found “encour-
ging” evidence that dual RAS blockade reduced proteinuria by
0% to 25% more than either drug alone (8). The most recent
andmark study, the ONTARGET (Renal Outcomes With
elmisartan, Ramipril, or Both, in People at High Vascular
isk) study, is no exception in this regard (9). The increase in
lbuminuria was reduced with a combination of telmisartan
nd ramipril when compared with monotherapy. However, the
nding of significantly more doubling of the creatinine and
ialysis in the combination arm despite the lesser albuminuria
trongly argues against a nephroprotective effect of dual RAS
nhibition. Even in the large diabetic subgroup of more than
00 patients with overt (300 mg/g creatinine) proteinuria, in
hom the loss of GFR was several times faster than in patients
ithout diabetes, dual RAS blockade had no significant effect
n renal outcome when compared with ramipril alone or
elmisartan alone (R. Schmieder, personal communication,
ovember 2008).
These findings in the ONTARGET study clearly em-
hasize the fallacy of the surrogate end point (i.e., the
urrogate, albuminuria moves in the “right” direction
hereas the real end point, doubling of creatinine and
ialysis, moves in the opposite direction). This divergence
etween real end point and surrogate end point should not
e surprising in view of the experimental studies in sodium-
epleted animals (10). In this model, combined blockade of
he RAS led to loss of weight, increase in creatinine, and
eath—a sequence of events that was preventable with a
igh sodium diet. Although most of our hypertensive
atients are not sodium depleted, we should remember that
iuretic therapy is an exceedingly common therapeutic
pproach in essential hypertension, and diuretic-induced
olume depletion may be sufficient to cause harm in some
atients on dual RAS blockade.
Conversely, dietary sodium intake has been shown to
ffect albuminuria. Verhave et al. (11) found a correlation
etween dietary sodium intake and albumin excretion
ndependent of other risk factors such as blood pressure.
hus, sodium intake seems to be a double-edged sword in
atients on dual RAS blockade. A high-sodium diet may
bolish the antiproteinuric effects whereas a low-sodium
iet may lead to hypotension and a fall in glomerular
ltration rate.
eart Failure
he CHARM-Added (Effects of Candesartan in Patients
ith Chronic Heart Failure and Reduced Left-Ventricular
ystolic Function Taking Angiotensin-Converting-Enzyme
nhibitors) trial reported some benefits when candesartan
as added to an ACE inhibitor in patients with New York
eart Association functional class III to IV heart failure and
left ventricular ejection fraction of 40% or lower (12). Theddition of candesartan reduced all components of the arimary outcome, the total num-
er of hospital admissions for
HF, but not all-cause mortal-
ty. A meta-analysis looking at all
he studies in aggregate includ-
ng the CHARM-Added trial
ound no reduction in all-cause
ortality but a 23% reduction of
eart failure hospitalizations
13). Of note, in the CHARM-
dded trial, significantly more patients discontinued study
edication in the combination arm because of an adverse
vent or abnormal laboratory values (increase in creatinine,
yperkalemia) in the combination therapy arm than in the
lacebo/ACE inhibitor arm. Indeed, a recent thorough
eta-analysis looking at safety and tolerability of dual RAS
lockade in over 18,000 patients with left ventricular dys-
unction showed a significantly increased risk of adverse
vents leading to discontinuation of dual RAS blockade
ompared with monotherapy (14). Hypotension, worsening
f renal function, and hyperkalemia (odds ratios of 1.91,
.12, and 4.17, respectively) were more common with
ombination therapy than with the ACE inhibitor alone.
he authors concluded that this excess risk coupled with the
ack of a consistent mortality benefit suggested that ARBs
hould not routinely be added to ACE inhibitors for left
entricular dysfunction (14).
irect Renin Inhibitors
nd Aldosterone Antagonists
n a thorough prospective, randomized study of 599 patients,
ean urinary albumin to creatinine ratio was reduced by 20%
ore with dual RAS blockade of aliskiren and losartan than
ith losartan alone despite a very small difference in blood
ressure between the treatment groups (15). The authors,
pparently impressed by these results, enthusiastically con-
luded that “aliskiren appears to have a renoprotective effect
hat is independent of its blood pressure-lowering effect”
15). However, given the surrogate end point failure in the
NTARGET study, the extrapolation from albuminuria to
enal function is no longer acceptable. Clearly to establish
enefits, if any, of dual RAS blockade with direct renin
nhibitors, ironclad outcome data on renal function will have
o be provided.
In contrast, for dual RAS blockade with aldosterone
ntagonists such as spironolactone and eplerinone, both the
urrogate end point and real end point move in parallel.
hus, at least in heart failure, the benefits of adding
pironolactone or eplerinone to either an ACE inhibitor or
n ARB have been well documented.
onclusions
he recent ONTARGET study data (9) have shattered the
alo of dual RAS blockade not only for hypertension but
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blockade
RAS  renin-angiotensin
systemlso for nephroprotection. The meta-analysis of Lakhdar
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Sudden Demise of Dual RAS Blockade February 10, 2009:468–70t al. (14) has cast doubts on the safety of dual RAS
lockade in patients with left ventricular dysfunction. In
etrospect, many enticing features of dual RAS blockade
ere based on surrogate end point findings and, therefore,
ay have represented more wishful thinking rather than solid
cience. This would indicate that the Food and Drug Admin-
stration’s reluctance to accept albuminuria/proteinuria as a
alid surrogate is well founded (16). Leapfrogging of surrogate
ata can no longer substitute for patient exposure in clinical
utcome studies (17). Unless data emerge to the contrary, dual
AS blockade is dead until further notice.
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